KA
Director, Research & Development
Get the full picture
Sign in to uncover key details.
Elios Therapeutics
Blood & Organ Banks · South Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
111 Smith Hines Rd Ste E, Greenville, So...Website
www.eliostherapeutics.comRevenue
<$5 MillionIndustry
About Elios Therapeutics
Elios Therapeutics specializes in personalized therapeutic cancer vaccines, focusing on patients with solid tumors. Founded in 2014, the company leverages innovative transgenic technology developed by Dr. Thomas Wagner to create autologous vaccines that enhance the immune system's ability to target and destroy tumor cells. Their lead product, the Tumor Lysate, Particle Only (TLPO) vaccine, aims to provide a safe and effective immunotherapy option for patients, particularly those at high risk of melanoma recurrence. Elios Therapeutics is committed to advancing cancer treatment through personalized medicine and ongoing clinical trials.Explore more
Elios Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Elios Therapeutics
Compare insights from companies similar to Elios Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Elios Therapeutics Tech Stack
A closer look at the technologies used by Elios Therapeutics
See more technologies
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elios Therapeutics
Sign Up For FreeTo access detailed company insights
Elios Therapeutics specializes in personalized therapeutic cancer vaccines, focusing on patients with solid tumors. Founded in 2014, the company leverages innovative transgenic technology developed by Dr. Thomas Wagner to create autologous vaccines that enhance the immune system's ability to target and destroy tumor cells. Their lead product, the T... Read More
